10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2014 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2014 10-K (Filed: Feb 27, 2015) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | |
| Cash Flow From (Used in) Operating Activities: | |||
| Net earnings | $ 2,284 | 2,576 | 5,963 |
| Adjustments to reconcile net earnings to net cash from operating activities - | |||
| Depreciation | 918 | 928 | 1,363 |
| Amortization of intangible assets | 630 | 791 | 1,419 |
| Share-based compensation | 246 | 262 | 433 |
| Acquired in-process and collaborations research and development | 288 | ||
| Investing and financing (gains) losses, net | 69 | 4 | 356 |
| Net loss on extinguishment of debt | 18 | 1,351 | |
| Trade receivables | (195) | (113) | 36 |
| Inventories | (297) | (154) | (417) |
| Prepaid expenses and other assets | 30 | 131 | (35) |
| Trade accounts payable and other liabilities | (225) | (436) | (134) |
| Income taxes | 197 | (665) | (1,309) |
| Net Cash From Operating Activities | 3,675 | 3,324 | 9,314 |
| Cash Flow From (Used in) Investing Activities: | |||
| Acquisitions of property and equipment | (1,077) | (1,145) | (1,795) |
| Acquisitions of businesses and technology, net of cash acquired | (3,317) | (580) | (706) |
| Purchases of investment securities | (1,507) | (10,064) | (11,998) |
| Proceeds from sales of investment securities | 5,624 | 7,839 | 8,936 |
| Other | 75 | 21 | 3 |
| Net Cash (Used in) Investing Activities | (202) | (3,929) | (5,560) |
| Cash Flow From (Used in) Financing Activities: | |||
| Proceeds from issuance of (repayments of) short-term debt and other | 1,343 | 2,086 | 784 |
| Proceeds from issuance of long-term debt and debt with maturities over 3 months | 9 | 14,700 | |
| Repayments of long-term debt and debt with maturities over 3 months | (577) | (303) | (11,071) |
| Acquisition and contingent consideration payments related to business acquisitions | (400) | (495) | (521) |
| Transfer of cash and cash equivalents to AbbVie Inc. | (5,901) | ||
| Purchases of common shares | (2,195) | (1,605) | (2,364) |
| Proceeds from stock options exercised, including income tax benefit | 429 | 395 | 1,850 |
| Dividends paid | (1,342) | (882) | (3,183) |
| Net Cash (Used in) Financing Activities | (2,742) | (6,696) | 195 |
| Effect of exchange rate changes on cash and cash equivalents | (143) | (26) | 40 |
| Net Decrease (Increase) in Cash and Cash Equivalents | 588 | (7,327) | 3,989 |
| Cash and Cash Equivalents, Beginning of Year | 3,475 | 10,802 | |
| Cash and Cash Equivalents, End of Period | 4,063 | 3,475 | 10,802 |
| Supplemental Cash Flow Information: | |||
| Income taxes paid | 448 | 1,039 | 1,367 |
| Interest paid | 182 | 148 | 576 |
| External Links | |
| ABBOTT LABORATORIES (ABT) Fiscal Year 2014 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |